Plain-English translation of NCT06594640 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a newer form of a chemotherapy drug called , given together with four other standard cancer medications (rituximab, cyclophosphamide, vincristine, and prednisone). The goal is to see if this combination is safe and effective for people with newly diagnosed diffuse large B-cell lymphoma, an aggressive type of blood cancer.
Diffuse large B-cell lymphoma is a serious cancer that needs strong treatment. Researchers want to know if this newer form of the chemotherapy drug—which may work better and cause fewer side effects—can improve how well the standard treatment combination works.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination as an infusion (IV) once every 3 weeks, for up to 6 cycles (about 4.5 months total). The trial has two parts: in the first part, doctors will gradually increase the dose of the newer chemotherapy drug to find the safest and most effective dose; in the second part, you and other participants will receive that chosen dose. You will have regular blood tests, scans, and check-ups to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~108 participants
Started
May 2024
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wei Liu
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.